BACKGROUND: Objective adherence metrics for tenofovir (TFV) disoproxil fumarate/emtricitabine (FTC)-based pre-exposure prophylaxis (PrEP) were critical for interpretation of efficacy in PrEP clinical trials, and there is increasing interest in using drug levels to tailor interventions for reengagement and adherence. Point-of-care immunoassays for TFV, which examine short-term adherence, are in development. However, the ability of poor short-term and long-term adherence to predict future PrEP nonretention is unknown. SETTING: Secondary data analysis of a large, prospective multi-site U.S. PrEP demonstration project. METHODS: An adjusted Cox-proportional hazards model examined the relationship of dried blood spot (DBS) levels of FTC-triphosphate (FTC-TP) or TFV-diphosphate (TFV-DP), measures of short-term and long-term PrEP adherence, respectively, with future study nonretention. RESULTS: Overall, 294 individuals (median age 33 years) contributed drug levels within the U.S. PrEP demonstration project. By the end of study, 27% were lost to follow-up, 25% had at least one undetectable FTC-TP level indicating poor short-term adherence, and 29% had a drug level indicating suboptimal long-term adherence (TFV-DP <700 fmol/punch). The strongest factor associated with future study nonretention using a binary drug-level cut-off was an undetectable DBS FTC-TP level (adjusted hazard ratio 6.3; 95% confidence interval 3.8 to 10.2). The suboptimal long-term adherence based on low DBS TFV-DP levels was also associated with nonretention (adjusted hazard ratio 4.3; 95% confidence interval: 2.4 to 7.6). CONCLUSIONS: Both short- and long-term metrics of PrEP adherence are strongly associated with future loss to follow-up in a U.S. demonstration project study. Short-term metrics of adherence, once available at the point-of-care, could be used to direct real-time tailored retention and adherence interventions.
BACKGROUND: Objective adherence metrics for tenofovir (TFV) disoproxil fumarate/emtricitabine (FTC)-based pre-exposure prophylaxis (PrEP) were critical for interpretation of efficacy in PrEP clinical trials, and there is increasing interest in using drug levels to tailor interventions for reengagement and adherence. Point-of-care immunoassays for TFV, which examine short-term adherence, are in development. However, the ability of poor short-term and long-term adherence to predict future PrEP nonretention is unknown. SETTING: Secondary data analysis of a large, prospective multi-site U.S. PrEP demonstration project. METHODS: An adjusted Cox-proportional hazards model examined the relationship of dried blood spot (DBS) levels of FTC-triphosphate (FTC-TP) or TFV-diphosphate (TFV-DP), measures of short-term and long-term PrEP adherence, respectively, with future study nonretention. RESULTS: Overall, 294 individuals (median age 33 years) contributed drug levels within the U.S. PrEP demonstration project. By the end of study, 27% were lost to follow-up, 25% had at least one undetectable FTC-TP level indicating poor short-term adherence, and 29% had a drug level indicating suboptimal long-term adherence (TFV-DP <700 fmol/punch). The strongest factor associated with future study nonretention using a binary drug-level cut-off was an undetectable DBSFTC-TP level (adjusted hazard ratio 6.3; 95% confidence interval 3.8 to 10.2). The suboptimal long-term adherence based on low DBSTFV-DP levels was also associated with nonretention (adjusted hazard ratio 4.3; 95% confidence interval: 2.4 to 7.6). CONCLUSIONS: Both short- and long-term metrics of PrEP adherence are strongly associated with future loss to follow-up in a U.S. demonstration project study. Short-term metrics of adherence, once available at the point-of-care, could be used to direct real-time tailored retention and adherence interventions.
Authors: Robert A Bonacci; Katherine Frasca; Lyles Swift; Daohang Sha; Warren B Bilker; Laura Bamford; Baligh R Yehia; Robert Gross Journal: AIDS Behav Date: 2016-05
Authors: Sybil G Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Siberry; Brandy Rutledge; Nancy Liu; Jennifer Brothers; Kathleen Mulligan; Gregory Zimet; Michelle Lally; Kenneth H Mayer; Peter Anderson; Jennifer Kiser; James F Rooney; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Sybil G Hosek; Raphael J Landovitz; Bill Kapogiannis; George K Siberry; Bret Rudy; Brandy Rutledge; Nancy Liu; D Robert Harris; Kathleen Mulligan; Gregory Zimet; Kenneth H Mayer; Peter Anderson; Jennifer J Kiser; Michelle Lally; Jennifer Brothers; Kelly Bojan; Jim Rooney; Craig M Wilson Journal: JAMA Pediatr Date: 2017-11-01 Impact factor: 16.193
Authors: Raphael J Landovitz; Matthew Beymer; Ryan Kofron; Kathy Rivet Amico; Christina Psaros; Lane Bushman; Peter L Anderson; Risa Flynn; David P Lee; Robert K Bolan; Wilbert C Jordan; Chi-Hong Tseng; Rhodri Dierst-Davies; Jim Rooney; Amy Rock Wohl Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731
Authors: Susanne Doblecki-Lewis; Albert Y Liu; Daniel J Feaster; Stephanie E Cohen; Richard Elion; Oliver Bacon; Megan Coleman; Gabriel Cardenas; Michael A Kolber Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Catherine A Koss; Sybil G Hosek; Peter Bacchetti; Peter L Anderson; Albert Y Liu; Howard Horng; Leslie Z Benet; Karen Kuncze; Alexander Louie; Parya Saberi; Craig M Wilson; Monica Gandhi Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Philip A Chan; Leandro Mena; Rupa Patel; Catherine E Oldenburg; Laura Beauchamps; Amaya G Perez-Brumer; Sharon Parker; Kenneth H Mayer; Matthew J Mimiaga; Amy Nunn Journal: J Int AIDS Soc Date: 2016-06-13 Impact factor: 5.396
Authors: Joseph N Mwangi; William M Gilliland; Nicole White; Craig Sykes; Amanda Poliseno; Kelly A Knudtson; Lisa Hightow-Weidman; Angela D M Kashuba; Elias P Rosen Journal: Antimicrob Agents Chemother Date: 2022-03-10 Impact factor: 5.938
Authors: Monica Gandhi; Guohong Wang; Roger King; Warren C Rodrigues; Michael Vincent; David V Glidden; Tim R Cressey; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Oraphan Siriprakaisil; Virat Klinbuayaem; Nelly R Mugo; Kenneth Ngure; Paul K Drain; Jared M Baeten Journal: AIDS Date: 2020-02-01 Impact factor: 4.632
Authors: William C Goedel; S Bessey; Mark N Lurie; Katie B Biello; Patrick S Sullivan; Amy S Nunn; Brandon D L Marshall Journal: AIDS Date: 2020-08-01 Impact factor: 4.632
Authors: Ayokunle O Olanrewaju; Benjamin P Sullivan; Jane Y Zhang; Andrew T Bender; Derin Sevenler; Tiffany J Lo; Marta Fernandez-Suarez; Paul K Drain; Jonathan D Posner Journal: ACS Sens Date: 2020-04-15 Impact factor: 9.618